Sun Pharmaceutical has received the Australian Therapeutic Goods Administration (TGA) approval for its speciality product, Ilumya (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Ilumya selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL23 receptor leading to inhibition of the release…
FDA Approves Sun Pharma’s Dry Eye Treatment
Sun Pharmaceutical has received approval for Cequa (cyclosporine ophthalmic solution) 0.09 percent, from the U.S. FDA. Cequa is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). Cequa provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first and only approved CsA product that incorporates a nanomicellar technology. The innovative nanomicellar formulation…